Enteris BioPharma

Enteris BioPharma is a clinical-stage biopharmaceutical contract development and manufacturing organization. It develops Peptelligence, an oral drug delivery technology platform. The company also offers Ovarest, a product candidate and is being evaluated for its potential to treat endometriosis.
TypeSubsidiary
Parent CompanySWK Holdings
HQBoonton, NJ, US
Founded2013
Websiteenterisbiopharma.com
Cybersecurity ratingBMore
Enteris BioPharma was founded in 2013 and is headquartered in Boonton, NJ, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Enteris BioPharma

Rajiv Khosla

Rajiv Khosla

Chief Executive Officer
Brian Zietsman

Brian Zietsman

President & CFO
Paul Shields

Paul Shields

Chief Operating Officer
Gary A. Shangold

Gary A. Shangold

Chief Medical Officer
Show more

Enteris BioPharma Office Locations

Enteris BioPharma has an office in Boonton
Boonton, NJ, US (HQ)
83 Fulton St
Show all (1)

Enteris BioPharma Financials and Metrics

Summary Metrics

Founding Date

2013
Enteris BioPharma is a subsidiary of SWK Holdings

Enteris BioPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Enteris BioPharma Online and Social Media Presence

Embed Graph

Enteris BioPharma News and Updates

Enteris BioPharma Receives 2021 Best of Boonton Award

BOONTON, N.J., Aug. 23, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that it has received the...

Enteris BioPharma to Host Webinar on High Potency Active Pharmaceutical Ingredients in Oral Drug Development

BOONTON, N.J., June 15, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company will host...

Enteris BioPharma to Participate in BIO Digital 2021

BOONTON, N.J., June 7, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), today announced that the company is...

Enteris BioPharma Announces Dr. John Vrettos to Host Webinar on Advances in Oral Delivery of Peptide Therapeutics

BOONTON, N.J., Sept. 15, 2020 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company will...

Enteris BioPharma to Participate in BIO International Digital Convention

BOONTON, N.J., June 2, 2020 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company is...

Enteris BioPharma Blogs

The 505(b)(2) Pathway – Pharma’s “Goldilocks” Opportunity

Discovery and development of new medicines to extend or improve the life of patients is a challenging and expensive endeavor. The cost of developing a new drug is estimated to be between $800 million and $2 billion and often requires 10 or more years of development with the FDA only approving, on av…

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics

Third milestone payment related to the development of Oral KORSUVA™   Dallas, TX, June 11, 2021  — SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty […] The post SWK Holdings’ Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics appear…

AAPS PharmSci 360

October 17-20 Philadelphia, PA The post AAPS PharmSci 360 appeared first on Enteris Biopharma.

Enteris BioPharma Completes Expansion of Manufacturing Facility, Announces Launch of CDMO Business Segment

CDMO Business Driven by Custom Solutions from Bench to Market for the Development and Manufacture of Difficult to Formulate Drugs and Highly Potent Compounds   BOONTON, […] The post Enteris BioPharma Completes Expansion of Manufacturing Facility, Announces Launch of CDMO Business Segment appeared fi…

SMALL MOLECULE THERAPEUTICS: Solubility with Permeability to Achieve Better Bioavailability

Proteins and peptides are the building blocks of life and are a very promising basis for targeting a range of diseases. Throughout the past 30 years, and especially the past 10 years, there has been a rapid growth in the development of therapeutic proteins, with a significant increase in the number …

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics

Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October Dallas, TX, December 24, 2020 – SWK […] The post SWK Holdings’ Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics appeared firs…
Show more

Enteris BioPharma Frequently Asked Questions

  • When was Enteris BioPharma founded?

    Enteris BioPharma was founded in 2013.

  • Who are Enteris BioPharma key executives?

    Enteris BioPharma's key executives are Rajiv Khosla, Brian Zietsman and Paul Shields.

  • How many employees does Enteris BioPharma have?

    Enteris BioPharma has 21 employees.

  • Who are Enteris BioPharma competitors?

    Competitors of Enteris BioPharma include SubTerra, Frontier Medicines and TFF Pharmaceuticals.

  • Where is Enteris BioPharma headquarters?

    Enteris BioPharma headquarters is located at 83 Fulton St, Boonton.

  • Where are Enteris BioPharma offices?

    Enteris BioPharma has an office in Boonton.

  • How many offices does Enteris BioPharma have?

    Enteris BioPharma has 1 office.